Sabine Hilfiker

Leucine-rich repeat kinase 2 impairs the release sites of Parkinson's disease vulnerable dopamine axons

This study identifies LRRK2's role in impairing dopamine axon release sites in Parkinson's disease, leading to reduced dopamine release and synaptic dysfunction.

LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons

This study shows that LRRK2 kinase mediates haloperidol-induced motor side effects in striatal neurons, suggesting LRRK2 as a target to reduce antipsychotic side effects.

PAK6 rescues pathogenic LRRK2-mediated ciliogenesis and centrosomal cohesion defects in a mutation-specific manner

This study identifies PAK6 as a modifier of LRRK2 mutations, showing it rescues ciliogenesis defects in G2019S but not R1441C mutations.

Pathogenic LRRK2 causes age-dependent and region-specific deficits in ciliation, innervation and viability of cholinergic neurons

This study shows that pathogenic LRRK2 mutations cause age-dependent and region-specific deficits in ciliation, innervation, and viability of cholinergic neurons in mice.

A potential patient stratification biomarker for Parkinson's disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells

Peripheral blood-derived cells can be employed to stratify Parkinson's disease patients most likely to respond to LRRK2-related therapeutics.

Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease

This study shows that the LRRK2 G2019S mutation impairs EAAT2 trafficking, leading to reduced glutamate clearance and potential neurodegeneration in Parkinson's disease.

LRRK2 causes centrosomal deficits via phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages

This study shows that LRRK2 kinase activity causes centrosomal cohesion deficits through phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages.